Yale Child Study Center, New Haven, CT.
Therapix Biosciences, Tel Aviv, Israel.
Pain Physician. 2017 Jul;20(5):353-362.
Palmitoylethanolamide (PEA) is a cannabimimetic compound that has been investigated as an analgesic agent in animal models and clinical trials.
We conducted a meta-analysis to examine the efficacy of PEA for treating pain in randomized, controlled trials.
Systematic review and meta-analysis.
This meta-analysis examined all randomized, controlled trials involving the effect of PEA on pain score.
We searched PubMed and Embase for randomized, active or placebo-controlled trials of PEA for the treatment of acute or chronic pain. Our primary outcome was the weighted mean difference in visual analog pain scales of PEA treatment compared to inactive controls.
We identified 10 studies including data from 786 patients who received PEA and 512 controls for inclusion in our systematic review. Eight trials included an inactive control group and were included in the meta-analysis. PEA was associated with significantly greater pain reduction compared to inactive control conditions (WMD = 2.03, 95% CI: 1.19 - 2.87, z = 4.75, P < 0.001). Use of placebo control, presence of blinding, allowance for concomitant treatments, and duration or dose of PEA treatment did not affect the measured efficacy of PEA. All-cause dropout was non-significantly reduced in the PEA group compared to inactive control conditions (RR = 0.36, 95% CI: 0.10 - 1.26, z = -1.60, P = 0.11).
This meta-analysis relied on a relatively small number of trials across a variety of conditions causing pain with differing trial designs. Overall quality of the underlying studies and assessment of side effects were often poor.
PEA may be a useful treatment for pain and is generally well tolerated in research populations. Further, well-designed, randomized, placebo-controlled trials are needed to provide reliable estimates of its efficacy and to identify less serious adverse events associated with this compound.
PEA, palmidrol, palmitoylethanolamide, efficacy, pain, pain management, meta-analysis.
棕榈酰乙醇酰胺（PEA）是一种拟大麻化合物，已在动物模型和临床试验中被研究作为一种镇痛剂。
我们进行了一项荟萃分析，以检查 PEA 治疗疼痛的疗效在随机对照试验中。
系统评价和荟萃分析。
这项荟萃分析检查了所有涉及 PEA 对疼痛评分影响的随机、对照试验。
我们在 PubMed 和 Embase 中搜索了 PEA 治疗急性或慢性疼痛的随机、活性或安慰剂对照试验。我们的主要结局是 PEA 治疗与非活性对照相比的视觉模拟疼痛量表的加权均数差。
我们确定了 10 项研究，包括 786 名接受 PEA 治疗和 512 名对照的患者的数据，纳入我们的系统评价。八项试验包括非活性对照组，并纳入荟萃分析。PEA 与非活性对照相比，疼痛减轻显著更大（WMD = 2.03，95%CI：1.19-2.87，z = 4.75，P < 0.001）。使用安慰剂对照、存在盲法、允许同时治疗以及 PEA 治疗的持续时间或剂量均不影响 PEA 的测量疗效。与非活性对照相比，PEA 组的全因辍学率显著降低（RR = 0.36，95%CI：0.10-1.26，z = -1.60，P = 0.11）。
这项荟萃分析依赖于在各种引起疼痛的条件下进行的相对较少的试验，具有不同的试验设计。基础研究的整体质量和副作用评估往往较差。
PEA 可能是一种治疗疼痛的有效方法，在研究人群中通常具有良好的耐受性。此外，需要进行精心设计的、随机的、安慰剂对照试验，以提供其疗效的可靠估计，并确定与该化合物相关的不太严重的不良事件。
PEA，palmidrol，palmitoylethanolamide，疗效，疼痛，疼痛管理，荟萃分析。
